Skip to main content
. 2022 Oct 17;3(10):1181–1191. doi: 10.1038/s43018-022-00439-1

Extended Data Fig. 3. Deleterious ctDNA SNVs enriched at progression in non-responders.

Extended Data Fig. 3

Deleterious ctDNA SNVs enriched 5-fold in progression samples from non-responders (change of SLD > -20%) compared to baseline. Deleterious variants identified in tumor WES are also shown. N = 9 patients.

Source data